Location, biophysical and agronomic parameters for croplands in northern Ghana

Smallholder agriculture is the bedrock of the food production system in sub-Saharan Africa. Yields in Africa are significantly below potentially attainable yields for a number of reasons, and they are particularly vulnerable to climate change impacts. Monitoring of these highly heterogeneous landscapes is needed to respond to farmer needs, develop an appropriate policy and ensure food security, and Earth observation (EO) must be part of these efforts, but there is a lack of ground data for developing and testing EO methods in western Africa, and in this paper, we present data on (i) crop locations, (ii) biophysical parameters and (iii) crop yield, and biomass was collected in 2020 and 2021 in Ghana and is reported in this paper. In 2020, crop type was surveyed in more than 1800 fields in three different agroecological zones across Ghana (the Guinea Savannah, Transition and Deciduous zones). In 2021, a smaller number of fields were surveyed in the Guinea Savannah zone, and additionally, repeated measurements of leaf area index (LAI) and leaf chlorophyll concentration were made on a set of 56 maize fields. Yield and biomass were also sampled at harvesting. LAI in the sampled fields ranged from 0.1 to 5.24 m2 m−2, whereas leaf chlorophyll concentration varied between 6.1 and 60.3 µg cm−2. Yield varied between 190 and 4580 kg ha−1, with an important within-field variability (average per-field standard deviation 381 kg ha−1). The data are used in this paper to (i) evaluate the Digital Earth Africa 2019 cropland masks, where 61 % of sampled 2020/21 cropland is flagged as cropland by the data set, (ii) develop and test an LAI retrieval method from Earth observation Planet surface reflectance data (validation correlation coefficient R=0.49, root mean square error (RMSE) 0.44 m2 m−2), (iii) create a maize classification data set for Ghana for 2021 (overall accuracy within the region tested: 0.84), and (iv) explore the relationship between maximum LAI and crop yield using a linear model (correlation coefficient R=0.66 and R=0.53 for in situ and Planet-derived LAI, respectively). The data set, made available here within the context of the Group on Earth Observations Global Agricultural Monitoring (GEOGLAM) initiative, is an important contribution to understanding crop evolution and distribution in smallholder farming systems and will be useful for researchers developing/validating methods to monitor these systems using Earth observation data. The data described in this paper are available from https://doi.org/10.5281/zenodo.6632083 (Gomez-Dans et al., 2022)

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity

Objective: Glucagon/glucagon-like peptide-1 (GLP-1) receptor co-agonists may provide greater weight loss than agonists targeting the GLP-1 receptor alone. We report results from three phase 1 trials investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of the glucagon/GLP-1 receptor co-agonist NNC9204-1177 (NN1177) for once-weekly subcutaneous use in adults with overweight or obesity. Methods: Our focus was a 12-week, multiple ascending dose (MAD), placebo-controlled, double-blind trial in which adults (N = 99) received NN1177 (on an escalating dose regimen of 200, 600, 1300, 1900, 2800, 4200 and 6000 μg) or placebo. Two other trials also contributed to the findings reported in this article: a first human dose (FHD)/single ascending dose (SAD), placebo-controlled, double-blind trial in which adults (N = 49) received NN1177 (treatment doses of 10, 40, 120, 350, 700 and 1100 μg) or placebo, and a drug–drug interaction, open-label, single-sequence trial in which adults (N = 45) received a 4200-μg dose of NN1177, following administration of a Cooperstown 5 + 1 index cocktail. Safety, tolerability, pharmacokinetic and pharmacodynamic endpoints were assessed. Results: For the FHD/SAD and MAD trials, baseline characteristics were generally balanced across treatment cohorts. The geometric mean half-life of NN1177 at steady state was estimated at between 77 and 111 h, and clinically relevant weight loss was achieved (up to 12.6% at week 12; 4200 μg in the MAD trial). Although NN1177 appeared tolerable across trials, several unexpected treatment-related safety signals were observed; increased heart rate, decreased reticulocyte count, increased markers of inflammation (fibrinogen and C-reactive protein), increased aspartate and alanine aminotransferase, impaired glucose tolerance and reduced blood levels of some amino acids. Conclusion: Although treatment with NN1177 was associated with dose-dependent and clinically relevant weight loss, the observed safety signals precluded further clinical development

AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study

Background Oral imatinib has been shown to be effective, but poorly tolerated, in patients with advanced pulmonary arterial hypertension (PAH). To maintain efficacy while improving tolerability, AV-101, a dry powder inhaled formulation of imatinib, was developed to deliver imatinib directly to the lungs. Methods This phase 1, placebo-controlled, randomised single ascending dose (SAD) and multiple ascending dose (MAD) study evaluated the safety/tolerability and pharmacokinetics of AV-101 in healthy adults. The SAD study included five AV-101 cohorts (1 mg, 3 mg, 10 mg, 30 mg, 90 mg) and placebo, and a single-dose oral imatinib 400-mg cohort. The MAD study included three AV-101 cohorts (10 mg, 30 mg, 90 mg) and placebo; dosing occurred twice daily for 7 days. Results 82 participants (SAD n=48, MAD n=34) were enrolled. For the SAD study, peak plasma concentrations of imatinib occurred within 3 h of dosing with lower systemic exposure compared to oral imatinib (p<0.001). For the MAD study, systemic exposure of imatinib was higher after multiple doses of AV-101 compared to a single dose, but steady-state plasma concentrations were lower for the highest AV-101 cohort (90 mg) compared to simulated steady-state oral imatinib at day 7 (p=0.0002). Across AV-101 MAD dose cohorts, the most common treatment-emergent adverse events were cough (n=7, 27%) and headache (n=4, 15%). Conclusions AV-101 was well tolerated in healthy adults, and targeted doses of AV-101 significantly reduced the systemic exposure of imatinib compared with oral imatinib. An ongoing phase 2b/phase 3 study (IMPAHCT; clinicaltrials.gov identifier NCT05036135) will evaluate the safety/tolerability and clinical benefit of AV-101 for PAH

Students' participation in collaborative research should be recognised

Letter to the editor

Body mass index and complications following major gastrointestinal surgery: A prospective, international cohort study and meta-analysis

Aim Previous studies reported conflicting evidence on the effects of obesity on outcomes after gastrointestinal surgery. The aims of this study were to explore the relationship of obesity with major postoperative complications in an international cohort and to present a metaanalysis of all available prospective data. Methods This prospective, multicentre study included adults undergoing both elective and emergency gastrointestinal resection, reversal of stoma or formation of stoma. The primary end-point was 30-day major complications (Clavien\u2013Dindo Grades III\u2013V). A systematic search was undertaken for studies assessing the relationship between obesity and major complications after gastrointestinal surgery. Individual patient meta-analysis was used to analyse pooled results. Results This study included 2519 patients across 127 centres, of whom 560 (22.2%) were obese. Unadjusted major complication rates were lower in obese vs normal weight patients (13.0% vs 16.2%, respectively), but this did not reach statistical significance (P = 0.863) on multivariate analysis for patients having surgery for either malignant or benign conditions. Individual patient meta-analysis demonstrated that obese patients undergoing surgery formalignancy were at increased risk of major complications (OR 2.10, 95% CI 1.49\u20132.96, P &lt; 0.001), whereas obese patients undergoing surgery for benign indications were at decreased risk (OR 0.59, 95% CI 0.46\u20130.75, P &lt; 0.001) compared to normal weight patients. Conclusions In our international data, obesity was not found to be associated with major complications following gastrointestinal surgery. Meta-analysis of available prospective data made a novel finding of obesity being associated with different outcomes depending on whether patients were undergoing surgery for benign or malignant disease